Key facts
- QV Bioelectronics’s last known valuation is $10.3M (Jan 2023).
- It has raised $10.4M; the latest was Later Stage VC ($6.0M) in Jan 2026.
- Notable investors include Innovate UK, Creative Destruction Lab, SOSV, Texas Medical Center, Empirical Ventures — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for QV Bioelectronics
- ·The full record, as it builds
Funding rounds
No funding rounds for QV Bioelectronics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About QV Bioelectronics
Developer of an implanted electric field therapy device designed to treat brain tumors. The company's device uses electric fields at specific frequencies to interrupt normal cancer cell growth cycles, slowing down tumour growth while sparing healthy tissue, enabling surgeons to improve survival and quality of life for brain tumour patients.
- Sector
- Healthcare
- HQ
- Macclesfield, United Kingdom
- Founded
- 2018
- Employees
- 19
- Website
- qvbio.co.uk/
- Ownership
- Privately Held (backing)
QV Bioelectronics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in QV Bioelectronics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on QV Bioelectronics in its N-PORT filings yet. We sweep new filings monthly.